Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.67 |
| ▸ | MTOR | P42345 | 4/20 | 0.64 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.63 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | PRKACG | P22612 | 1/20 | 0.63 |
| ▸ | PRKACB | P22694 | 1/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960919 | 0.86 | PIK3CA (0.87) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL964649 | 0.85 | PIK3CA (0.86) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL12464157 | 0.85 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL960078 | 0.84 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL958760 | 0.84 | PIK3CA (0.86) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL29439930 | 0.84 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL959755 | 0.83 | PIK3CA (0.81) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL28799921 | 0.83 | PIK3CA (0.77) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL10316567 | 0.82 | PIK3CA (0.81) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL17255579 | 0.82 | PIK3CA (0.83) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | PIK3CA 4464/4885PIK3CG 4388/4885PIK3CD 4347/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885PIK3CG 6/4885PIK3CD 5/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | PIK3CA 4464/4885PIK3CG 4388/4885PIK3CD 4347/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | PIK3CA 4464/4885PIK3CG 4388/4885PIK3CD 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.